Asthma

The Pharmacy Times® Asthma resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.

What can we help you find?
[[thumbnail_alt_text]]
Advancements in the understanding of asthma pathophysiology has led to the discovery of defined asthma phenotypes and targeted interventions involving novel biologic therapies.
[[thumbnail_alt_text]]
A recent study demonstrated that budesonide-formoterol is superior to albuterol for as-needed exacerbation prevention in mild asthma.
[[thumbnail_alt_text]]
Benralizumab is a monoclonal antibody that binds directly to the IL-5 receptor alpha on eosinophils and attracts natural killer cells to induce rapid depletion of eosinophils via programmed cell death.
[[thumbnail_alt_text]]
Can MH safely take albuterol instead of levalbuterol?
[[thumbnail_alt_text]]
The results of a study of almost 500,000 women indicate that taking paracetamol or other painkillers during pregnancy does not increase the risk of asthma in children.
[[thumbnail_alt_text]]
Pivotal phase 3 trial results show benefits for once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI; Trelegy Ellipta) in patients with uncontrolled asthma compared with standard FF/VI (Breo Ellipta) therapy.
[[thumbnail_alt_text]]
The results of a new study by George Washington University show that about 4 million children worldwide develop asthma annually because of nitrogen dioxide inhalation through air pollution.
[[thumbnail_alt_text]]
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.
[[thumbnail_alt_text]]
The new phase 2 data for an investigational once-daily, fixed dose combination currently in development for the treatment of inadequately controlled asthma was presented at the 2019 Annual International Congress of the American Thoracic Society (ATS) in Dallas.
[[thumbnail_alt_text]]
Pivotal phase 3 trial results show benefits for once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI; Trelegy Ellipta) in patients with uncontrolled asthma compared with standard FF/VI (Breo Ellipta) therapy.
[[thumbnail_alt_text]]
Pharmacists have a great opportunity to educate patients about how to stay healthy and counsel those in need of symptom relief about their allergy treatment options.